Common use of Non-Contravention of Existing Instruments Clause in Contracts

Non-Contravention of Existing Instruments. No Further Authorizations or Approvals Required 5 (o) No Material Actions or Proceedings 6 (p) Intellectual Property 6 (q) All Necessary Permits, etc 7 (r) Title to Properties 7 (s) Tax Law Compliance 7 (t) Company Not an “Investment Company” 7 (u) Insurance 8 (v) No Price Stabilization or Manipulation 8 (w) Related Party Transactions 8 (x) Disclosure Controls and Procedures 8 (y) No Unlawful Contributions or Other Payments 8 (z) Company’s Accounting System 8 (aa) Compliance with Environmental Laws 9 (bb) ERISA Compliance 9 (cc) Brokers 11 (dd) No Outstanding Loans or Other Indebtedness 11 (ee) Compliance with Laws 11 (ff) No Labor Disputes 11 (gg) Material Contracts 11 (hh) No Margin Securities 11 (ii) Forward-Looking Statements 11 (jj) Xxxxxxxx-Xxxxx Act of 2002 11 (kk) Corporate Governance 12 (ll) NASD Affiliations 12 (mm) Communication with the FDA 12 (nn) Studies and Other Preclinical and Clinical Tests 12 (oo) Due Diligence 12

Non-Contravention of Existing Instruments. No Further Authorizations or Approvals Required 5 6 (on) No Material Actions or Proceedings 6 (po) Intellectual Property 6 Rights 7 (qp) All Necessary Permits, etc 7 (rq) Title to Properties 7 (sr) Tax Law Compliance 7 (ts) Company Not an “Investment Company” 7 Company 8 (ut) Insurance 8 (vu) No Price Stabilization or Manipulation 8 (wv) Related Party Transactions 8 (xw) Disclosure Controls and Procedures Exchange Act Compliance 8 (yx) No Unlawful Contributions or Other Payments 8 9 (zy) Company’s Accounting System 8 9 (aaz) Compliance with Environmental Laws 9 (aa) Periodic Review of Costs of Environmental Compliance 10 (bb) ERISA Compliance 9 10 (cc) Brokers 11 10 (dd) No Outstanding Loans or Other Indebtedness 11 10 (ee) Compliance with Laws 10 B. REPRESENTATIONS AND WARRANTIES OF THE SELLING STOCKHOLDERS 11 (ffa) The Underwriting Agreement 11 (b) Title to Common Shares to be Sold; All Authorizations Obtained 11 (c) Delivery of the Common Shares to be Sold 11 (d) Non-Contravention; No Further Authorizations or Approvals Required 12 (e) No Labor Disputes 11 Registration or Other Similar Rights 12 (gg) Material Contracts 11 (hhf) No Margin Securities 11 (ii) Forward-Looking Statements 11 (jj) Xxxxxxxx-Xxxxx Act of 2002 11 (kk) Corporate Governance Further Consents, etc 12 (llg) NASD Affiliations Disclosure Made by Such Selling Stockholder in the Prospectus 12 Table of Contents (mm) Communication with the FDA 12 (nn) Studies and Other Preclinical and Clinical Tests 12 (oo) Due Diligence 12continued)

Non-Contravention of Existing Instruments. No Further Authorizations or Approvals Required 5 9 (o) No Material Actions or Proceedings 6 10 (p) Intellectual Property 6 Rights 10 (q) All Necessary Permits, etc 7 Etc 11 (r) FCC Licenses 11 (s) Network Affiliation Agreements 12 (t) Local Services Agreements 12 (u) Condition of Stations 12 (v) Title to Properties 7 12 (sw) Tax Law Compliance 7 12 (tx) Company Not an “Investment Company” 7 13 (uy) Insurance 8 13 (vz) No Price Stabilization or Manipulation 8 13 (w) Related Party Transactions 8 (x) Disclosure Controls and Procedures 8 (y) No Unlawful Contributions or Other Payments 8 (zaa) Company’s Accounting System 8 (aa) Compliance with Environmental Laws 9 13 (bb) ERISA Compliance 9 13 (cc) Brokers 11 (dd) No Outstanding Loans or Other Indebtedness 11 14 (eedd) Compliance with Laws 11 14 (ee) Foreign Assets Control Regulations, Etc 15 (ff) No Labor Disputes 11 Status under Certain Statutes 15 SECTION 2. Purchase, Sale and Delivery of the Securities 15 (gga) Material Contracts 11 (hh) No Margin The Securities 11 (ii) Forward-Looking Statements 11 (jj) Xxxxxxxx-Xxxxx Act of 2002 11 (kk) Corporate Governance 12 (ll) NASD Affiliations 12 (mm) Communication with the FDA 12 (nn) Studies and Other Preclinical and Clinical Tests 12 (oo) Due Diligence 1215

Non-Contravention of Existing Instruments. No Further Authorizations or Approvals Required 5 (o) No Material Actions or Proceedings 6 (p) Intellectual Property 6 (q) All Necessary Permits, etc 7 (r) Title to Properties 7 (s) Tax Law Compliance 7 (t) Company Not an “Investment Company” 7 (u) Insurance 8 (v) No Price Stabilization or Manipulation 8 (w) Related Party Transactions 8 (x) Disclosure Controls and Procedures 8 (y) No Unlawful Contributions or Other Payments 8 (z) Company’s Accounting System 8 (aa) Compliance with Environmental Laws 9 (bb) ERISA Compliance 9 (cc) Brokers 11 (dd) No Outstanding Loans or Other Indebtedness 11 (ee) Compliance with Laws 11 (ff) No Labor Disputes 11 (gg) Material Contracts 11 (hh) No Margin Securities 11 (ii) Forward-Looking Statements 11 (jj) Xxxxxxxx-Xxxxx Act of 2002 11 (kk) Corporate Governance 12 (ll) NASD Affiliations 12 (mmll) Communication with the FDA 12 (nnmm) Studies and Other Preclinical and Clinical Tests 12 (oonn) Due Diligence 12

Non-Contravention of Existing Instruments. No Further Authorizations or Approvals Required 5 (o) No Material Actions or Proceedings 6 (p) Intellectual Property 6 (q) All Necessary Permits, etc 7 (r) Title to Properties 7 (s) Tax Law Compliance 7 (t) Company Not an “Investment Company” 7 (u) Insurance 8 (v) No Price Stabilization or Manipulation 8 (w) Related Party Transactions 8 (x) Disclosure Controls and Procedures 8 (y) No Unlawful Contributions or Other Payments 8 (z) Company’s Accounting System 8 9 (aa) Compliance with Environmental Laws 9 (bb) ERISA Compliance 9 (cc) Brokers 11 (dd) No Outstanding Loans or Other Indebtedness 11 (ee) Compliance with Laws 11 (ff) No Labor Disputes 11 (gg) Material Contracts 11 (hh) No Margin Securities 11 (ii) Forward-Looking Statements 11 (jj) XxxxxxxxSxxxxxxx-Xxxxx Act of 2002 11 12 (kk) Corporate Governance 12 (ll) NASD Affiliations 12 (mm) Communication with the FDA 12 (nn) Studies and Other Preclinical and Clinical Tests 12 (oo) Due Diligence 12